{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-007071","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.353984+00:00","generated_at":"2026-05-15T19:38:47.289330+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Phio Pharma reports 2025 net loss $8.7M; PH-762 Phase 1b dose escalation complete with favorable data","bullets":["Net loss of $8.7M ($1.45 EPS) for 2025 vs $7.2M ($9.08 EPS) in 2024; R&D expenses up 27%.","Cash at Dec 31, 2025: $21.0M vs $5.4M year ago; net proceeds from 2025 financings of $20.6M extend runway into H1 2027.","PH-762 Phase 1b dose escalation trial fully enrolled (22 patients); final cohort shows favorable safety, tolerability and pathology.","FDA submission seeking guidance on next steps for PH-762 targeted for Q2 2026; patent portfolio includes 54 issued patents.","Phio entered drug substance development agreement with US manufacturer and toxicology study agreement with US lab in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-007071","json":"https://secwatch.observer/filing/0001437749-26-007071.json","markdown":"https://secwatch.observer/filing/0001437749-26-007071.md","text":"https://secwatch.observer/filing/0001437749-26-007071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926007071/0001437749-26-007071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926007071/phio20251215_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:38:47.289330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}